Advertisement
Screener

EVOLUS, INC. (EOLS) Increase (Decrease) in Deferred Liabilities

2.8 / 5 stars · 68/120 Roast Me

EVOLUS, INC. Increase (Decrease) in Deferred Liabilities

EVOLUS, INC. (EOLS) reported Increase (Decrease) in Deferred Liabilities of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-25.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2020-02-25

  • EVOLUS, INC. increase (decrease) in deferred liabilities for the quarter ending 2019-12-31 was $0.00.
  • EVOLUS, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-12-31 was -$5.00K.
  • EVOLUS, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-09-30 was -$3.00K.
  • EVOLUS, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-06-30 was -$3.00K.
  • EVOLUS, INC. increase (decrease) in deferred liabilities for fiscal 2019 was $0.00.
  • EVOLUS, INC. increase (decrease) in deferred liabilities for fiscal 2018 was -$13.00K.
  • EVOLUS, INC. increase (decrease) in deferred liabilities for fiscal 2017 was -$6.00K.
Period endIncrease (Decrease) in Deferred Liabilities 3 monthIncrease (Decrease) in Deferred Liabilities 6 monthIncrease (Decrease) in Deferred Liabilities 9 monthIncrease (Decrease) in Deferred Liabilities 12 month
2019-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
$0.00
10-K · filed 2020-02-25
2019-09-30$0.00
10-Q · filed 2019-11-04
2018-12-31-$5.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25
-$8.00K
derived: sum of 2 quarters · filed 2020-02-25
-$11.00K
derived: sum of 3 quarters · filed 2020-02-25
-$13.00K
10-K · filed 2020-02-25
2018-09-30-$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04
-$6.00K
derived: sum of 2 quarters · filed 2019-11-04
-$8.00K
10-Q · filed 2019-11-04
-$9.00K
derived: sum of 4 quarters · filed 2019-11-04
2018-06-30-$3.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
-$5.00K
10-Q · filed 2018-08-02
-$6.00K
derived: sum of 3 quarters · filed 2019-03-20
-$9.00K
derived: sum of 4 quarters · filed 2019-03-20
2018-03-31-$2.00K
10-Q · filed 2018-05-10
-$3.00K
derived: sum of 2 quarters · filed 2019-03-20
-$6.00K
derived: sum of 3 quarters · filed 2019-03-20
-$8.00K
derived: sum of 4 quarters · filed 2019-03-20
2017-12-31-$1.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20
-$4.00K
derived: sum of 2 quarters · filed 2019-03-20
-$6.00K
derived: sum of 3 quarters · filed 2019-03-20
-$6.00K
10-K · filed 2019-03-20
2017-09-30-$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05
-$5.00K
derived: sum of 2 quarters · filed 2018-11-05
-$5.00K
10-Q · filed 2018-11-05
2017-06-30-$2.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02
-$2.00K
10-Q · filed 2018-08-02
2017-03-31$0.00
10-Q · filed 2018-05-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
ARVINAS, INC. (ARVN)United States$0.510B58.38
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
Indaptus Therapeutics, Inc. (INDP)United States$0.537B
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
Ovid Therapeutics Inc. (OVID)United States$0.487B-14.41
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
Phathom Pharmaceuticals, Inc. (PHAT)United States$0.572B-8.76
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Altimmune, Inc. (ALT)United States$0.593B-6.43